Cleveland Clinic

The field of endocrinology saw many advancements in 2024 and more developments and innovations are anticipated in 2025.

SAN DIEGO — The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than reported in prior clinical trials, according to study results.

Over the past decade, I have been fortunate to have a platform on which to reflect about the varying dimensions of empathy as it applies to medical practice, and in particular its relevancy to the field of rheumatology.

Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune response, according to updated results of a phase 1 trial.

SAN DIEGO — Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings achieved worse survival outcomes than those who received the agents in pivotal trials.

For the second time since 2019, the oral SGLT1 and SGLT2 dual inhibitor sotagliflozin has been denied FDA approval for adults with type 1 diabetes, with elevated risk for diabetic ketoacidosis being a primary concern.

U.S. Surgeon General Vivek Murthy, MD, MBA, issued an advisory today that includes several recommendations designed to reduce the impact of alcohol on cancer incidence and mortality.

In this Healio video exclusive, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, outlines the December issue’s top stories, including an in-depth feature on how practices can handle the rising threat of cyberattacks.

SAN ANTONIO — In this video, Halle Moore, MD, discusses the long-term results of the OlympiA trial presented at San Antonio Breast Cancer Symposium.

I have just returned and am recovering from #ACR24, and although there is a universe of things happening in our field, I want to focus for a moment on a rare, marginalized disease with a patient population desperately seeking effective care.